PetMed Express, Inc. (NASDAQ:PETS) was the recipient of a significant growth in short interest in the month of July. As of July 31st, there was short interest totalling 3,219,148 shares, a growth of 24.0% from the July 14th total of 2,596,931 shares. Currently, 16.3% of the company’s shares are sold short. Based on an average trading volume of 1,098,570 shares, the days-to-cover ratio is presently 2.9 days.

PetMed Express (PETS) opened at 47.76 on Friday. PetMed Express has a 52-week low of $18.90 and a 52-week high of $50.90. The firm has a 50 day moving average of $43.59 and a 200-day moving average of $30.19. The stock has a market cap of $969.15 million, a PE ratio of 36.74 and a beta of 0.99.

PetMed Express (NASDAQ:PETS) last posted its quarterly earnings results on Monday, July 24th. The company reported $0.45 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.38 by $0.07. The company had revenue of $79.66 million for the quarter, compared to the consensus estimate of $77.32 million. PetMed Express had a net margin of 10.34% and a return on equity of 28.67%. The firm’s revenue was up 9.9% compared to the same quarter last year. During the same quarter last year, the firm posted $0.32 EPS. Equities analysts anticipate that PetMed Express will post $1.44 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, August 18th. Shareholders of record on Monday, August 7th will be given a dividend of $0.20 per share. This represents a $0.80 dividend on an annualized basis and a yield of 1.68%. The ex-dividend date is Thursday, August 3rd. PetMed Express’s dividend payout ratio (DPR) is 61.54%.

In other PetMed Express news, Director Ronald J. Korn sold 5,000 shares of the business’s stock in a transaction dated Friday, July 28th. The shares were sold at an average price of $48.18, for a total value of $240,900.00. Following the transaction, the director now owns 67,333 shares in the company, valued at $3,244,103.94. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Robert C. Schweitzer sold 2,500 shares of the business’s stock in a transaction dated Tuesday, August 1st. The shares were sold at an average price of $49.18, for a total transaction of $122,950.00. Following the completion of the transaction, the director now owns 88,834 shares in the company, valued at approximately $4,368,856.12. The disclosure for this sale can be found here. Insiders sold 24,333 shares of company stock worth $1,126,330 in the last 90 days. Corporate insiders own 4.00% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Acadian Asset Management LLC acquired a new position in PetMed Express during the second quarter worth approximately $18,691,000. Oaktop Capital Management II L.P. acquired a new position in PetMed Express during the second quarter worth approximately $15,171,000. Vanguard Group Inc. increased its position in PetMed Express by 21.0% in the second quarter. Vanguard Group Inc. now owns 1,300,725 shares of the company’s stock worth $52,810,000 after buying an additional 225,474 shares during the period. Renaissance Technologies LLC increased its position in PetMed Express by 11.8% in the first quarter. Renaissance Technologies LLC now owns 1,786,315 shares of the company’s stock worth $35,976,000 after buying an additional 188,615 shares during the period. Finally, Dimensional Fund Advisors LP increased its position in PetMed Express by 24.0% in the first quarter. Dimensional Fund Advisors LP now owns 794,669 shares of the company’s stock worth $16,005,000 after buying an additional 153,709 shares during the period. 78.36% of the stock is currently owned by institutional investors and hedge funds.

PETS has been the topic of a number of analyst reports. Craig Hallum cut shares of PetMed Express from a “buy” rating to a “hold” rating in a research report on Tuesday, July 11th. Zacks Investment Research upgraded shares of PetMed Express from a “hold” rating to a “strong-buy” rating and set a $38.00 price objective on the stock in a research report on Wednesday, May 10th. Noble Financial restated a “hold” rating on shares of PetMed Express in a research report on Wednesday, July 26th. Finally, Northcoast Research upgraded shares of PetMed Express from a “neutral” rating to a “buy” rating and set a $54.00 price objective on the stock in a research report on Monday, July 24th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $35.00.

WARNING: “PetMed Express, Inc. (NASDAQ:PETS) Short Interest Update” was reported by American Banking News and is owned by of American Banking News. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/08/13/petmed-express-inc-nasdaqpets-short-interest-update.html.

About PetMed Express

PetMed Express, Inc (PetMed Express), doing business as 1800PetMeds, is a pet pharmacy. The Company markets prescription and non-prescription pet medications, and other health products for dogs and cats, direct to the consumer. It offers a selection of products for dogs and cats. Its product line contains approximately 3,000 stock keeping units (SKUS) of pet medications, health products and supplies.

Receive News & Ratings for PetMed Express Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetMed Express Inc. and related companies with MarketBeat.com's FREE daily email newsletter.